Key result
Oral administration of Milrinone in patients with severe congestive heart failure markedly increased cardiac output, decreased cardiac filling pressures, and rapidly decreased plasma ir-ANP levels.
Why the study?
Does acute treatment with oral milrinone alter plasma ir-ANP levels in patients with severe congestive heart failure?
Population
7 patients with severe congestive heart failure (CHF) undergoing cardiac catheterization
Design
Case_series
Follow-up
up to 2 hours
Authors
Loading...
ir-ANP may track atrial pressure changes in severe HF; hypothesis-generating for biomarker monitoring, needs prospective validation.
Does acute treatment with oral milrinone alter plasma ir-ANP levels in patients with severe congestive heart failure?
Plasma ir-ANP levels rapidly decrease when atrial pressure is reduced by milrinone, suggesting atrial pressure is the major determinant for its release and highlighting its potential as a monitoring tool in heart failure.
Berglund et al. (1988) studied Congestive heart failure (CHF) (n=7). Milrinone was evaluated on Plasma immunoreactive ANP (ir-ANP) levels. Oral administration of Milrinone in patients with severe congestive heart failure markedly increased cardiac output, decreased cardiac filling pressures, and rapidly decreased plasma ir-ANP levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: